JANSSEN VACCINES & PREVENTION BV

Their core work

Janssen Vaccines & Prevention (formerly Crucell Holland) is the vaccine development arm of Johnson & Johnson, based in Leiden, Netherlands. They develop prophylactic and therapeutic vaccines against major infectious diseases including Ebola, HIV, and malaria, with strong capabilities in clinical trial design, immunology platforms, and manufacturing scale-up. Their H2020 portfolio shows deep involvement in pandemic preparedness vaccines and growing work on antimicrobial resistance and aging-related immunology.

What they specialise in

How they've shifted over time

In the early H2020 period (2014-2017), Janssen Vaccines focused heavily on emergency response vaccine development — primarily Ebola (EBOVAC1/2, EBOMAN) and HIV (EHVA) — reflecting urgent pandemic preparedness priorities. From 2018 onward, their portfolio diversified significantly toward broader infectious disease challenges: malaria vaccines, aging population immunology, antimicrobial resistance prediction, and fundamental immunometabolism research. This shift suggests a strategic move from single-pathogen emergency response toward systemic, population-level vaccine and antibody strategies.

Janssen is moving from pathogen-specific emergency vaccine development toward population-health challenges like antimicrobial resistance and immunosenescence — expect growing interest in modelling, monoclonal antibodies, and vaccine impact assessment.

How they like to work

Janssen Vaccines participates exclusively as a consortium partner, never as coordinator — consistent with large pharma companies that contribute proprietary vaccine platforms and clinical infrastructure while leaving project management to academic or public-sector leads. With 118 unique partners across 27 countries, they operate in large, multi-national consortia (many IMI-funded), indicating comfort with complex governance structures. Their role is typically that of an industry partner providing vaccine candidates, manufacturing know-how, or clinical trial expertise to publicly-led research efforts.

Extensive network of 118 unique consortium partners spanning 27 countries, reflecting participation in large IMI and RIA consortia. Their reach is genuinely global in scope, with collaborations extending well beyond the EU through pandemic-response projects.

What sets them apart

As a major pharmaceutical vaccine developer (part of Johnson & Johnson), Janssen brings industrial-scale vaccine manufacturing, proprietary adenoviral vector platforms (Ad26), and GMP-grade clinical development capabilities that academic partners simply cannot match. Their sustained commitment to the EBOVAC program — spanning three consecutive projects from Phase I through licensure — demonstrates follow-through rare among H2020 industry participants. For consortium builders, they offer the credibility and regulatory pathway expertise needed to move research from lab bench to approved product.

Highlights from their portfolio

• EBOVAC3
  Final phase bringing the Ebola vaccine to licensure — represents the culmination of a decade-long, three-project pipeline (EBOVAC1→2→3) that is one of H2020's most visible public health success stories.
• PrIMAVeRa
  Their most recent project (2021-2026) signals a strategic pivot toward antimicrobial resistance, combining vaccines and monoclonal antibodies with mathematical modelling — a forward-looking research direction.
• EHVA
  EU-wide HIV vaccine alliance combining prophylactic and therapeutic approaches with innovative trial design and data integration across multiple European research groups.